FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017022669> ?p ?o ?g. }

• W2017022669 endingPage "478.e5" @default.
• W2017022669 startingPage "472" @default.
• W2017022669 abstract "Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary intervention (PCI) among patients with atrial fibrillation (AF) rely on retrospective, nonrandomized observational data. Currently, patients are treated with triple-therapy (dual antiplatelet therapy [DAPT] + oral anticoagulation therapy), but neither the duration of DAPT nor the level of anticoagulation has been studied in a randomized fashion. Recent studies also suggest dual pathway therapy with clopidogrel plus oral anticoagulation therapy may be superior, and other studies suggest that novel oral anticoagulants such as rivaroxaban may further improve patient outcomes. PIONEER AF-PCI (ClinicalTrials.gov NCT01830543) is an exploratory, open-label, randomized, multicenter clinical study assessing the safety of 2 rivaroxaban treatment strategies and 1 vitamin K antagonist (VKA) treatment strategy in subjects who have paroxysmal, persistent, or permanent nonvalvular AF and have undergone PCI with stent placement. Approximately 2,100 subjects will be randomized in a 1:1:1 ratio to receive either rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 months (a WOEST trial–like strategy), or rivaroxaban 2.5 mg twice daily (with stratification to a prespecified duration of DAPT 1, 6, or 12 months, an ATLAS trial–like strategy), or dose-adjusted VKA once daily (with stratification to a prespecified duration of DAPT 1, 6, or 12 months, traditional triple therapy). All patients will be followed up for 12 months for the primary composite end point of Thrombolysis in Myocardial Infarction major bleeding, bleeding requiring medical attention, and minor bleeding (collectively, clinically significant bleeding). The PIONEER AF-PCI study is the first randomized comparison of VKA vs novel oral anticoagulant therapy in patients with NVAF receiving antiplatelet therapy after PCI to assess the relative risks of bleeding complications." @default.
• W2017022669 created "2016-06-24" @default.
• W2017022669 creator A5014287819 @default.
• W2017022669 creator A5016139987 @default.
• W2017022669 creator A5017098029 @default.
• W2017022669 creator A5027772602 @default.
• W2017022669 creator A5032199684 @default.
• W2017022669 creator A5038405190 @default.
• W2017022669 creator A5039466154 @default.
• W2017022669 creator A5044800174 @default.
• W2017022669 creator A5052994249 @default.
• W2017022669 creator A5056162349 @default.
• W2017022669 creator A5065978967 @default.
• W2017022669 creator A5070062505 @default.
• W2017022669 date "2015-04-01" @default.
• W2017022669 modified "2023-10-18" @default.
• W2017022669 title "An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)" @default.
• W2017022669 cites W1986506316 @default.
• W2017022669 cites W1990680911 @default.
• W2017022669 cites W1999468381 @default.
• W2017022669 cites W2026900324 @default.
• W2017022669 cites W2094757280 @default.
• W2017022669 cites W2096606175 @default.
• W2017022669 cites W2097854437 @default.
• W2017022669 cites W2114775432 @default.
• W2017022669 cites W2115602184 @default.
• W2017022669 cites W2117677020 @default.
• W2017022669 cites W2126206943 @default.
• W2017022669 cites W2127090290 @default.
• W2017022669 cites W2132505348 @default.
• W2017022669 cites W2135694398 @default.
• W2017022669 cites W2159193915 @default.
• W2017022669 cites W2159370853 @default.
• W2017022669 cites W2327850977 @default.
• W2017022669 doi "https://doi.org/10.1016/j.ahj.2014.12.006" @default.
• W2017022669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25819853" @default.
• W2017022669 hasPublicationYear "2015" @default.
• W2017022669 type Work @default.
• W2017022669 sameAs 2017022669 @default.
• W2017022669 citedByCount "131" @default.
• W2017022669 countsByYear W20170226692015 @default.
• W2017022669 countsByYear W20170226692016 @default.
• W2017022669 countsByYear W20170226692017 @default.
• W2017022669 countsByYear W20170226692018 @default.
• W2017022669 countsByYear W20170226692019 @default.
• W2017022669 countsByYear W20170226692020 @default.
• W2017022669 countsByYear W20170226692021 @default.
• W2017022669 countsByYear W20170226692022 @default.
• W2017022669 countsByYear W20170226692023 @default.
• W2017022669 crossrefType "journal-article" @default.
• W2017022669 hasAuthorship W2017022669A5014287819 @default.
• W2017022669 hasAuthorship W2017022669A5016139987 @default.
• W2017022669 hasAuthorship W2017022669A5017098029 @default.
• W2017022669 hasAuthorship W2017022669A5027772602 @default.
• W2017022669 hasAuthorship W2017022669A5032199684 @default.
• W2017022669 hasAuthorship W2017022669A5038405190 @default.
• W2017022669 hasAuthorship W2017022669A5039466154 @default.
• W2017022669 hasAuthorship W2017022669A5044800174 @default.
• W2017022669 hasAuthorship W2017022669A5052994249 @default.
• W2017022669 hasAuthorship W2017022669A5056162349 @default.
• W2017022669 hasAuthorship W2017022669A5065978967 @default.
• W2017022669 hasAuthorship W2017022669A5070062505 @default.
• W2017022669 hasBestOaLocation W20170226692 @default.
• W2017022669 hasConcept C126322002 @default.
• W2017022669 hasConcept C141071460 @default.
• W2017022669 hasConcept C164705383 @default.
• W2017022669 hasConcept C168563851 @default.
• W2017022669 hasConcept C204243189 @default.
• W2017022669 hasConcept C2776301958 @default.
• W2017022669 hasConcept C2776704044 @default.
• W2017022669 hasConcept C2777028646 @default.
• W2017022669 hasConcept C2777849778 @default.
• W2017022669 hasConcept C2778661090 @default.
• W2017022669 hasConcept C2779161974 @default.
• W2017022669 hasConcept C2780400711 @default.
• W2017022669 hasConcept C45393284 @default.
• W2017022669 hasConcept C500558357 @default.
• W2017022669 hasConcept C71924100 @default.
• W2017022669 hasConceptScore W2017022669C126322002 @default.
• W2017022669 hasConceptScore W2017022669C141071460 @default.
• W2017022669 hasConceptScore W2017022669C164705383 @default.
• W2017022669 hasConceptScore W2017022669C168563851 @default.
• W2017022669 hasConceptScore W2017022669C204243189 @default.
• W2017022669 hasConceptScore W2017022669C2776301958 @default.
• W2017022669 hasConceptScore W2017022669C2776704044 @default.
• W2017022669 hasConceptScore W2017022669C2777028646 @default.
• W2017022669 hasConceptScore W2017022669C2777849778 @default.
• W2017022669 hasConceptScore W2017022669C2778661090 @default.
• W2017022669 hasConceptScore W2017022669C2779161974 @default.
• W2017022669 hasConceptScore W2017022669C2780400711 @default.
• W2017022669 hasConceptScore W2017022669C45393284 @default.
• W2017022669 hasConceptScore W2017022669C500558357 @default.
• W2017022669 hasConceptScore W2017022669C71924100 @default.
• W2017022669 hasIssue "4" @default.
• W2017022669 hasLocation W20170226691 @default.
• W2017022669 hasLocation W20170226692 @default.
• W2017022669 hasLocation W20170226693 @default.
• W2017022669 hasLocation W20170226694 @default.

• next